Companies expecting competition from Celgene multiple sclerosis candidate ozanimod just got a reprieve. The big biotech revealed late Tuesday that the FDA refused to accept its approval application because of “incomplete” pharmacology data. And that means more time for its future rivals to rack up sales unchallenged.Original Article
Biogen, Novartis, Sanofi catch a break with holdup to Celgene MS prospect
